MARKET

NTLA

NTLA

Intellia Therape
NASDAQ
12.16
-0.17
-1.38%
After Hours: 12.16 0 0.00% 16:21 09/24 EDT
OPEN
12.13
PREV CLOSE
12.33
HIGH
12.21
LOW
11.62
VOLUME
4.37M
TURNOVER
--
52 WEEK HIGH
28.25
52 WEEK LOW
7.95
MARKET CAP
1.70B
P/E (TTM)
-3.6228
1D
5D
1M
3M
1Y
5Y
1D
Crispr Therapeutics: Why AI Giant Anthropic's Discovery Has Rocked Gene Editing
Seeking Alpha · 1h ago
AM Markets Need to Know: F-35 parts end up in Chinese custody, Google nears Gemini 4 launch, and more
Seeking Alpha · 10h ago
Gene editing stocks fall after report on Anthropic’s CRISPR-like discovery
Seeking Alpha · 1d ago
Weekly Report: what happened at NTLA last week (0914-0918)?
Weekly Report · 3d ago
Cathie Wood's Ark weekly recap: buys Meta, gene-editing stocks while cutting Alphabet
Seeking Alpha · 09/14 11:10
Weekly Report: what happened at NTLA last week (0907-0911)?
Weekly Report · 09/14 09:49
Cathie Wood Sells $28.6M of Google Stock and Buys $26.4 M of Meta Shares. What Else Is She Buying? September 10
TipRanks · 09/10 11:30
Cathie Wood’s ARK Investment buys 204K shares of Intellia Therapeutics today
TipRanks · 09/10 00:10
More
About NTLA
Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies and other core technologies. CRISPR/Cas9 is a gene editing technology that leverages the body’s natural processes to precisely edit DNA. The Company is developing lonvoguran ziclumeran (lonvo-z), referred to as NTLA-2002, for the treatment of hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) also referred to as NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. It is focused on completing late-stage clinical development of its lead product candidates, lonvo-z for the treatment of patients with HAE and nex-z for the treatment of patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) and hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Its lead product candidates are the first in vivo genome editing product candidates into Phase III development. Its other pipeline products include REGV131-LNP1265 and AVC-201 & AVC-203.

Webull offers Intellia Therapeutics Inc stock information, including NASDAQ: NTLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NTLA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NTLA stock methods without spending real money on the virtual paper trading platform.